Stryker Corp. (NYSE: SYK) — This global specialty surgical and medical products company is expected to see a 12% increase in sales this year, led by the acquisition of Boston Scientific’s (NYSE: BSX) neurovascular unit.
S&P looks for earnings of $3.72 this year, up from $3.33, and they project earnings of $4.15 in 2012. On Feb. 23, UBS raised SYK to a “buy” from a “hold.”
Technically, the break from the double-top could give a trading target of $74. SYK was recommended as one of my Top Stocks for March. It is performing as expected and remains one of my top stock picks.
If you have questions or comments for Sam Collins, please e-mail him at samailc@cox.net.
Comments are currently unavailable. Please check back soon.